{{Rsnum
|rsid=11160533
|Gene=LOC100507108
|Chromosome=14
|position=99609436
|Orientation=plus
|GMAF=0.3838
|Gene_s=FAM193A
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 2.7 | 36.0 | 61.3
| HCB | 8.8 | 42.3 | 48.9
| JPT | 9.7 | 38.9 | 51.3
| YRI | 64.6 | 31.3 | 4.1
| ASW | 47.4 | 45.6 | 7.0
| CHB | 8.8 | 42.3 | 48.9
| CHD | 11.9 | 49.5 | 38.5
| GIH | 3.0 | 18.8 | 78.2
| LWK | 51.8 | 40.0 | 8.2
| MEX | 24.1 | 48.3 | 27.6
| MKK | 23.1 | 51.9 | 25.0
| TSI | 2.9 | 27.5 | 69.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs11160533
|Name_s=
|Gene_s=CCDC85C
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.29, combined P value= 1.65E-04. It is also associated with greater methotrexate clearance.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470202
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11160533
|overall_frequency_n=80
|overall_frequency_d=128
|overall_frequency=0.625
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=63
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}